{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T05:44:15Z","timestamp":1758347055452,"version":"3.44.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ijtb.2025.02.014","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T11:11:52Z","timestamp":1740049912000},"page":"489-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of 6 months isoniazid versus 3 months isoniazid - rifampicin therapy for prevention of tuberculosis in children suffering from tuberculosis infection - A randomized controlled trial"],"prefix":"10.1016","volume":"72","author":[{"given":"Shivangi","family":"Sinhal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geetika","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrish","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanda","family":"Chhavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Digvijay","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.M.A.","family":"Faridi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2025.02.014_bib1","unstructured":"Revised National Tuberculosis Control Programme National Strategic Plan for Tuberculosis Elimination 2017\u20132025. Available From: https:\/\/tbcindia.gov.in\/WriteReadData\/NSP%20Draft%2020.02.2017%201.pdf. Last Assessed on July2024."},{"key":"10.1016\/j.ijtb.2025.02.014_bib2","unstructured":"India National TB Prevalence Survey report (2019-2021). Available From: https:\/\/tbcindia.mohfw.gov.in\/annual-reports\/. Last Assessed on July2024."},{"key":"10.1016\/j.ijtb.2025.02.014_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(24)00083-3","article-title":"Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing studies","author":"Martinez","year":"2024","journal-title":"Lancet Respir Med"},{"year":"2018","series-title":"Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management","key":"10.1016\/j.ijtb.2025.02.014_bib4"},{"issue":"RR-1","key":"10.1016\/j.ijtb.2025.02.014_bib5","first-page":"1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep (Morb Mortal Wkly Rep)"},{"issue":"10","key":"10.1016\/j.ijtb.2025.02.014_bib6","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/17512433.2017.1366311","article-title":"Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?","volume":"10","author":"Alfarisi","year":"2017","journal-title":"Expet Rev Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ijtb.2025.02.014_bib7","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1186\/s12879-020-05449-x","article-title":"Tubercular infection in children living with adults receiving Directly Observed Treatment Short Course (DOTS): a follow up study","volume":"20","author":"Srivastava","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"8","key":"10.1016\/j.ijtb.2025.02.014_bib8","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/adc.2010.182600","article-title":"Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children","volume":"95","author":"Bright-Thomas","year":"2010","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.ijtb.2025.02.014_bib9","unstructured":"WHO operational handbook on tuberculosis: module 2: screening: systematic screening for tuberculosis disease. Available From: https:\/\/www.who.int\/publications\/i\/item\/9789240022614, Last Assessed on July 2024."},{"issue":"3-4","key":"10.1016\/j.ijtb.2025.02.014_bib10","first-page":"167","article-title":"Compliance with latent tuberculosis treatment: a public health challenge","volume":"153","author":"Bishara","year":"2014","journal-title":"Harefuah"},{"key":"10.1016\/j.ijtb.2025.02.014_bib11","unstructured":"Paediatric TB Management Guideline 2022: Ministry of Health and Family Welfare. Available on: http:\/\/tbcindia.gov.in. Last Assessed on January 2024."},{"issue":"5","key":"10.1016\/j.ijtb.2025.02.014_bib12","article-title":"Use of isoniazid monotherapy in Comparison to rifamycin-based regimen for the treatment of patients with latent tuberculosis: a systematic review","volume":"14","author":"Shahid","year":"2022","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.ijtb.2025.02.014_bib13","first-page":"1235","article-title":"Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada","volume":"12","author":"Hirsch-Moverman","year":"2008","journal-title":"Int J Tubercul Lung Dis"},{"issue":"2","key":"10.1016\/j.ijtb.2025.02.014_bib14","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1097\/PHH.0000000000000822","article-title":"High completion rate for 12 weekly doses of isoniazid and rifapentine as treatment for latent Mycobacterium tuberculosis infection in the Federal Bureau of Prisons","volume":"25","author":"Schmit","year":"2019","journal-title":"J Publ Health Manag Pract"},{"issue":"1","key":"10.1016\/j.ijtb.2025.02.014_bib15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12879-017-2377-x","article-title":"Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses","volume":"17","author":"Pease","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.ijtb.2025.02.014_bib16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/jac\/dky403","article-title":"Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study","volume":"74","author":"Doan","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.ijtb.2025.02.014_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02048-2019","article-title":"Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs","volume":"55","author":"Ronald","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ijtb.2025.02.014_bib18","first-page":"13","article-title":"Adherence to anti-tuberculosis chemoprophylaxis and treatment in children","volume":"10","author":"van Zyl","year":"2006","journal-title":"Int J Tubercul Lung Dis"},{"issue":"6","key":"10.1016\/j.ijtb.2025.02.014_bib19","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3390\/ijms17060960","article-title":"Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis","volume":"17","author":"Galli","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ijtb.2025.02.014_bib20","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/520983","article-title":"The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study","volume":"45","author":"Spyridis","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijtb.2025.02.014_bib21","article-title":"Adherence to isoniazid preventive therapy among under-five children in contact with adult bacteriologically confirmed pulmonary tuberculosis patients: a mixed-method study","volume":"2020","author":"Seid","year":"2020","journal-title":"Internet J Microbiol"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570725000460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570725000460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T04:08:26Z","timestamp":1758254906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570725000460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0019570725000460"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2025.02.014","relation":{},"ISSN":["0019-5707"],"issn-type":[{"type":"print","value":"0019-5707"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of 6 months isoniazid versus 3 months isoniazid - rifampicin therapy for prevention of tuberculosis in children suffering from tuberculosis infection - A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2025.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Tuberculosis Association of India. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}